A second generic version of the abortion pill mifepristone approved by FDA

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hullo! Today, we talk about Amgen’s positive new PCSK9 data, learn more about the new NIH office meant to reduce reliance on animal testing, and more. 

Amgen’s Repatha trial shows heart risk reduction

Amgen said yesterday that its cholesterol-lowering injection Repatha cut the risk of a composite of heart disease death, heart attacks, and strokes in a 12,000-patient trial, bolstering hopes for wider use of PCSK9 inhibitors after years of slow adoption, STAT’s Matt Herper writes.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $399/year

$30 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In